Rydén A. Coping and personality in the obese. Dept for Internal Medicine, Medical Faculty, Göteborg University, 2003.

Engström C.-P, Persson L-O, Larsson S, Rydén A, Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking. A descriptive and comparative study. Thorax, 1996, 51(8):825-830.

Montgomery H, Persson L-O, Rydén A. Importance and attainment of life values among disabled and non-disabled people. Scand J Rehab Med, 1996, 28:233-240.

Rydén A, Karlsson J, Persson L-O, Sjöström L, Taft C, Sullivan M. Obesity-related coping and distress and relations to treatment preference. Brit J Clin Psychol, 2001, 40:177-188.

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. Linkages between coping and psychological outcome in the spinal cord lesioned: development of SCL-related measures. Spinal Cord, 2002, 40:23-29.

Elfström M, Kreuter M, Rydén A, Persson L-O, Sullivan, M. Effects of coping on psychological outcome when controlling for background variables: a study of traumatically spinal cord lesioned persons. Spinal Cord, 2002, 40:408-415.

Rydén A, Karlsson J, Sullivan M, Torgerson J S, Taft C. Coping and distress: What happens after intervention? A 2-year follow-up from the Swedish Obese Subjects (SOS) study. Psychosom Med, 2003, 65 (3):435-442.

Rydén A, Sullivan M, Torgerson J S, Karlsson J, Lindroos A-K, Taft C. Severe obesity and personality: A comparative controlled study of personality traits. Int J Obes, 2003, 27:1534-1540

Rydén A, Sullivan M, Torgerson J S, Karlsson J, Lindroos A-K, Taft C. A comparative controlled study of personality in severe obesity: A two-year follow-up after intervention. Int J Obes, 2004, 28:1485-1493.

Elfström M, Rydén A, Kreuter, M, Taft C, Sullivan M. Relations between of coping strategies and health-related quality of life in patients with spinal cord lesion. J Rehab Med, 2005, 37:9-16.

Persson L-O, Engström C-P, Rydén A, Larsson S, Sullivan M. Life values in COPD patients, relation to pulmonary functioning, perceived functional status and mood: a comparative and follow-up study. Quality Life Res, 2005, 14:349-359.

Persson L-O, Rydén A. Themes of effective coping in physical disability: An interview study of 26 persons who have learnt to live with their disability. Scand J Caring Sci, 2006; 20:355-366.

Karlsson J, Rydén A, Sjöström L, Sullivan M, Taft C. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity - the SOS intervention study. Int J Obes, 2007, 31:1248-1261.

Johansson M, Finizia C, Degl’ Innocenti A, Rydén A. Is a line the same as a box? Speech assessments by VAS is not superior to Likert scales in laryngeal cancer patients. Med Sci Monit, 2007, 13:CR481-487.

Johansson M, Rydén A, Finizia C. Self-evaluation of communication experiences after laryngeal cancer – A longitudinal questionnaire study in patients with laryngeal cancer. BMC Cancer, 2008, 8:80.

Risberg-Berlin B, Rydén A, Ylitalo R, Finizia R. Development of a clinical instrument improving rehabilitation of olfaction with the Nasal Airflow-Inducing Maneuver in Swedish laryngectomized patients. Acta Otolaryngol, 2008, 31:1-7.

Risberg-Berlin B, Rydén A, Ylitalo R, Finizia R. Effects of total laryngectomy on olfactory function, health-related quality of life, and communication: a 3-year follow-up study. BMC Ear Nose Throat Disord, 2009, 9:8.

Sundberg T, Petzold M, Wändell P, Rydén A, Falkenberg T. Exploring integrative medicine for back and neck pain – a pragmatic randomised clinical trial. BMC Complementary Alternative Med, 2009, 9:33.

Andersson O, Rydén A, Ruth M, Ylitalo Möller R, Finizia C. Validation of a laryngopharyngeal reflux questionnaire, the Pharyngeal Reflux Symptom Questionnaire. Scand J Gastroenterol, 2010, 45:147-159.

Andersson O, Rydén A, Ruth M, Ylitalo Möller R, Finizia C. Validation of the Swedish translation of LPR-HRQL. Med Sci Monit, 2010, 16:CR480-87.

Johansson M, Rydén A, Finizia C. Mental adjustment to cancer and its relation to anxiety, depression, HRQL, and survival in patients with laryngeal cancer – A longitudinal study. BMC Cancer, 2011, 11:283.

Finizia C, Rudberg I, Bergqvist H, Rydén A. A cross-sectional validation study of the Swedish version of SWAL-QOL. Dysphagia, 2012, 27:325-35.

Johansson M, Finizia C, Ahlberg K, Rydén A. “Setting Boundaries” – Mental Adjustment to Cancer in Laryngeal Cancer Patients: An interview study. Eur J Oncol Nurs, 2012, 16;419-425.

Carlsson S, Rydén A, Bove M, Bergquist H, Finizia C. Validation of the Swedish M. D. Anderson Dysphagia Inventory (MDADI) in patients with head and neck cancer and neurologic swallowing disturbances. Dysphagia, 2012, 27:361-369.

Vakil N, Björck K, Denison H, Halling K, Karlsson M, Paty J, Silberg DG, Rydén A. Validation of the Reflux Symptom Questionnaire electronic Diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol, 2012, 3, e7; doi:10.1038/ctg.2012.1.

Johnson J, Carlsson S, Johansson M, Pauli N, Rydén A, Fagerberg-Mohlin B, Finizia C. Development and validation of the Gothenburg Trismus Questionnaire (GTQ). Oral Onc, 2012, 48:730-736.

Rydén A, Martin M, Halling K, Niklasson A. Nighttime symptoms and their impact on sleep in patients with a partial response to proton pump inhibitor therapy. The Patient – Patient Centered Outcomes Research, 2013, 6:307-314.

Rydén A, Denison H, Karlsson M, Vakil N. Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. Scand J Gastroenter,2013, 48:1018-26.

Johnson J, Johansson M, Rydén A, Houltz E, Finizia C. Impact of trismus on health-related quality of life and mental health. Head and Neck, 2015, 37:1672-1679.

Vakil N, Niklasson A, Denison H, Rydén A. Symptom profile in partial responders to proton pump inhibitor compared with treatment-naïve patients with Gastroesophageal reflux disease. BMC Gastroenterology, 2014, 14:177.

Vakil N, Niklasson A, Denison H, Rydén A. Gender differences in symptoms in partial responders to proton pump inhibitors for gastro-oesophageal reflux disease. UEG Journal, 2015, 3: 443–452.

Grandy S, Sternhufvud C, Rydén A, Sugg J, Rohwedder K. Patient-reported outcomes among Type 2 Diabetes Mellitus patients treated with Dapagliflozin triple therapy regimen for 52 weeks. Diab Obes Metab. 2016 Mar;18(3):306-9.

Rydén A, Wolfe M, Martin M. Patient-reported symptoms and perceptions of treatment success: a qualitative interview study in patients with end-stage renal disease undergoing hemodialysis. J Clin Nephrol Ren Care, 2016, 2:005.

Rydén A, Leavy OC, Halling K, Stone A. Comparison of daily versus weekly recording of gastroesophageal reflux disease symptoms in patients with a partial response to proton pump inhibitor therapy. Value in Health, 2016,19:829-833.

Rydén A, Sörstadius E, Bergenheim K, Romanovschi A, Thorén F, Witt E, Sternhufvud C. The humanistic burden of Type 1 Diabetes Mellitus in Europe: Examining health outcomes and the role of complications. PLOS One 2016, Nov 3;11(11):e0164977.

Rydén A, Chen S, Flood E, Romero B, Grandy S. Discrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with type 2 diabetes mellitus. The Patient, 2017, 10:475-487.

Reaney M, McHorney CA, Curtis B, Rydén A, Chassany O, Gwaltney C. Using individual experiences with experimental medications to predict medication-taking behaviour post-authorization - a DIA study endpoints workstream. Therapeutic Innovation & Regulatory Science, 2017.

Rydén A, Blackhall F, Kim HR, Pillai RN, Braam L, Martin M, Walding A. Patient experience of symptoms and side effects when treated with osimertinib (AZD9291) for advanced non-small-cell lung cancer: a qualitative Interview substudy. The Patient, 2017, 10:593-603.

Niklasson A, Paty J, Rydén A. Talking about breast cancer: Which symptoms and treatment side effects are important to patients? The Patient, 2017, 10:719-727.

Coyne K, Edvardsson N, Rydén A. Development and validation of the AFImpact™: an atrial fibrillation-specific measure of patient-reported health-related quality of life. Value in Health, 2017, 20:1355-1361.

Kluetz P, Kanapuru B Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger C, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O’Connor D, Patel S, Rubin EH, Rydén A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Policy Perspective: Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome (PRO) Measures: Summary of an FDA and Critical Path Institute Workshop. Value in Health, 2017, 21:742-747.

Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy in advanced non-small cell lung cancer - the AURA3 trial. J Clin Oncol, 2018, 36:1853-1860.

Sebastian M, Rydén A, Walding A, Papadimitrakopoulou V. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2018, 122:100-106.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab after chemoradiation in stage III, unresectable non-small cell-lung cancer (PACIFIC): a randomised, controlled phase 3 study. Lancet Oncol, 2019, 20;1670-1680.

Leighl N, Karaseva N, Nakagawa K, Cho BC, Gray J, Hovey T, Walding A, Rydén A, Novello S. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. Eur J Cancer, 2020, 125:49-57.

Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D,Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, Stage III non-small-cell lung cancer. Future Oncol, 2021, 17:1165-1184.

Martin M, Corell J, Walding A, Rydén A. How patients being treated for NSCLC value treatment benefit regardless of side effects. Quality of Life Research, 2022, 31:135-146.

Flythe J, Karlsson N, Sundgren A, Cordero P, Grandinetti A, Cremisi H, Rydén A. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis. BMC Nephrology, 2021, 22:233. doi.org/10.1186/s12882-021-02440-9

Martin M, Chung H, Rydén A. Willingness to report treatment-related symptoms of immunotherapy among patients with non-small-cell lung cancer. Quality of Life Research, 2022, 31:1147-1155.

Niklasson A, Maher J, Patil R, Sillén H, Chen J, Gwaltney J, Rydén A. Living with Heart Failure: Patient experiences and implications for physical activity and daily living. ESC Heart Failure, 2022, 9:1206-1215.

Walding A, Casamayor M, Skaltsa K, Rydén A. Definition of Time to Deterioration in NSCLC symptoms. Quality of Life Research, 2022, 31:2535-2543. doi.org/10.1007/s11136-022-03088-0

Rydén A, Nolan S, Maher J, Meyers O, Kündig A, Bjursell M. Understanding the experience of chronic kidney disease stages 2-3b: a qualitative interview study with Kidney Disease Quality of Life (KDQOL-36) debrief. BMC Nephrology 2022, 23:201. doi.org/10.1186/s12882-022-02826-3

Karlsson J, Rydén A, Taft C, Sullivan M. Health-related quality of life and obesity. Quality Life Newsletter, 2001, 26:10-11.

Karlsson J, Rydén A, Taft C, Sullivan M. Health-related quality of life and obesity. Obes Matters, 2001, 4:10-11.

Rydén A, Torgerson JS. The Swedish Obese Subjects Study – what has been accomplished so far? Surg Obes Relat Dis, 2006, 2:549-560.

Rolstad S, Adler J, Rydén A. Response burden and questionnaire length: Is shorter better? Review and Meta-analysis. Value in Health, 2011, 14:1101-1108.

Chassany O, Karlsson M, Shaheen N, Hughes N, Rydén A. Systematic review: Methodological aspects of patient-reported outcomes in gastroesophageal reflux disease and dyspepsia.  Scand J Gastroenterol, 2012, 47:1412-1421.

Vakil N, Halling K, Becher A, Rydén A. Systematic review of patient reported outcome instruments for gastroesophageal reflux disease symptoms. Eur J Gastroenterol Hepatol, 2013, 25:2-14.

Naegeli AN, Hanlon J, Gries KS, Safikhani S, Ryden A, Patel M, Crescioni M, Vernon M. Literature review to charactarize the empirical basis for response scale selection in pediatric populations. Patient-Reported Outcomes, 2018, 2:39.

Persson L-O, Rydén A. Adjustment and well-being among neurologically disabled. Life quality and Handicap, 1992.

Rydén A, Karlsson J, Persson L-O, Sjöström, L, Sullivan M. Swedish obese subjects (SOS) - An intervention study of obesity. What happens after surgery? ISOOL, Vienna, 1997 (Quality of Life Research, 1997, 6:712).

Rydén A, Karlsson J, Persson L-O, Sjöström, L, Sullivan M. Swedish obese subjects (SOS) – An intervention study of obesity. Mental health, personality and severe obesity – before and after surgery. International Congress on Obesity, Paris. Int J Obes, 1998, 22:78 (Suppl 3).

Torgerson JS, Rydén A, Karlsson J, Palaszewski B, Sullivan M, Sjöström L. BMI is more important than mental distress for cardiovascular risk factors in obese men. 3rd Nordic Obesity meeting, Lund, 2000.

Rydén A, Karlsson J, Palaszewski, B, Sjöström, L, Sullivan M, Torgerson JS. Health-related quality of life and cardiovacular risk factors in the obese: Are the relations the same for men and women? Annual meeting of the Swedish Medical Association, Göteborg, 2000.

Vakil N, Silberg DG, Björck K, Halling K, Paty J, Karlsson M, Denison H, Rydén A. Validation of a patient reported outcome instrument, the Reflux Symptom Questionnaire electronic Diary (RESQ-eD), in patients with a partial response to PPI therapy. DDW, Chicago. Gastroenerology 2011, 140:5 (Suppl 1);P S-67.

Du X, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Li J, Shen Z, Ryden A, Ahlqvist M, Sundén M, Karlson B W, Ma C. Rationale, design, and baseline characteristics of a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China (eHelp China). 27th Great Wall International Congress of Cardiology, Beijing, 2016.

Lee CK, Novello S, Rydén A, Templeton A, Rudell K, Mann H, Ghiorghiu S, Mok T. Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer. ELCC, Vienna, 2017.

Hui R, Özgüroğlu M, Daniel D, Baz DV, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab after chemoradiation in locally advanced, unresectable NSCLC: data from PACIFIC. WCLC, Yokohama, 2017.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Rydén A, Huang Y, Dennis PA, Antonia SJ. Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of Pacific patient-reported outcomes. ELCC, Geneva, 2018.

Nakagawa K, Leigh N, Karaseva N, Cho B, Gray J, Hovey T, Walding A, Rydén A, Novello S. Patient-reported outcomes from FLAURA: osimertininb vs SoC EGFR-TKI in patients with EGFR-mutated advanced NSCLC. JSMO, Kobe, 2018.

Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis PA, Antonia SJ. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, Stage III NSCLC (PACIFIC). ELCC, Geneva, 2019.

Persson, L.-O & Rydén, A. Adjustment and well being among neurologically disabled. Life quality and Handicap, Uppsala, 18-20 nov, 1992.

Rydén A, Persson L-O, Siösteen A, Sullivan M. A prospective study of emotional well-being in SCI persons. IMSOP’s (Int Med Soc Paraplegia) 36th Conferense, Innsbruck, 1997.

Rydén A, Persson L-O, Karlsson J, Sjöström L, Sullivan M. Swedish Obese Subjects (SOS) – an intervention study of obesity. How do they cope? European Conference on Obesity, Dublin (Int J Obes 1997, 21:S121).

Rydén A, Persson L-O, Karlsson J, Sjöström L, Sullivan M. Coping with severe obesity: What happens after surgery? ISOQOL, 1997 (Quality Life Res 1997, 6:712).

Rydén A, Karlsson J, Persson L-O, Sjöström L, Sullivan M. Mental health, personality and severe obesity – before and after surgery. European Congress on Obesity, 1998 (Int J Obes 1998, 22:78).

Rydén A, Karlsson J, Persson L-O, Sjöström L, Sullivan M. The Obesity-related Coping Questionnaire (OCQ) from the Swedish Obese Subjects (SOS) study. ISOQOL, Barcelona, 1999 (Quality Life Res 1999, 8:580).

Persson L-O, Engström C-P, Larsson S, Rydén A, Sullivan M. Importance and attainment of life values in chronic obstructive pulmonary disease (COPD). ISOQOL, 1999 (Quality Life Res 1999, 8:605).

Rydén A, Karlsson J, Persson L-O, Sjöström L, Sullivan M. Coping in relation to obesity: What happens after surgery? Annual meeting of the Swedish Medical Association, Stockholm, 1999.

Torgerson J S, Rydén A, Karlsson J, Palaszewski B, Sullivan M, Sjöström L. BMI is more important than mental distress for cardiovascular risk factors in obese men. 3rd Nordic Obesity Meeting, Lund, 2000.

Torgerson J S, Rydén A, Karlsson J, Palaszewski B, Sullivan M, Sjöström L. Mental distress less important than BMI for cardiovascular risk factors in obese men. European Congress on Obesity, Antwerpen, 2000 (Int J Obes 2000, 24:S140).

Rydén A, Taft C, Sullivan M. Testing the Hospital Anxiety and Depression Scale (HAD): What is best – two or three factors? ISOQOL, Vancouver, 2000 (Quality Life Res 2000, 9:334).

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. Linkages between coping and distress in spinal cord injury. ISOQOL, Vancouver, 2000 (Quality Life Res 2000, 9:282).

Rydén A, Karlsson J, Palaszewski B, Sjöström L, Sullivan M, Torgerson J S. Health-related quality of life and cardiovascular risk factors in obese patients: Are the relations similar for men and women? Annual meeting of the Swedish Medical Association, Göteborg, 2000.

Rydén A, Karlsson J, Palaszewski B, Torgerson J S, Sullivan M. Health-related quality of life and cardiovascular risk factors in the obese – are the relations similar in men and women? European Congress on Obesity, Vienna, 2001 (Int J Obes 2001, 25:126).

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. Linkages between coping and distress in the spinal cord lesioned. IMSOP’s (Int Med Soc Paraplegia) 40th Conferense, Nottwil, 2001.

Rydén A, Taft C, Sullivan M. Coping and distress before and after treatment. ISOQOL, Paris, 2001 (Quality Life Res 2001, 10(3):272).

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. Effects of coping on mental outcome in persons with spinal cord lesion. ISOQOL, 2001 (Quality Life Res 2001, 10:234).

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. Copingstrategiers effekt på psykiskt välbefinnande vid ryggmärgsskada. Annual meeting of the Swedish Medical Association, Stockholm, 2001.

Elfström M, Kreuter M, Rydén A, Persson L-O, Sullivan, M. Effects of coping on psychological outcome when controlling for background variables. IMSOP’s (Int Med Soc Paraplegia) 41st Conferense, Vancouver, 2002.

Elfström M, Rydén A, Kreuter M, Persson L-O, Sullivan M. The effect of coping strategies on general health-related quality of life among spinal injured patients. Annual meeting of the Swedish Medical Association, Göteborg, 2002.

Rydén A, Karlsson J, Lindroos A-K, Sullivan M, Torgerson JS, Taft C. Is there an obese personality? European Congress on Obesity, Helsinki, 2003 (Int J Obes 2003, 27:155).

Rydén A, Karlsson J, Lindroos A-K, Sullivan M, Torgerson J S, Taft C. Is there an obese personality? Annual meeting of the Swedish Medical Association, Stockholm, 2003.

Rydén A, Mattsson E-L, Sullivan M, Torgerson JS. The effect of diabetes complications on the prevalence of mental health in the obese. Annual meeting of the Swedish Medical Association, Stockholm, 2003.

Johansson M, Finizia C, Degl’ Innocenti A, Rydén A. Is a line the same as a box? Speech assessments by VAS is not superior to Likert scales in laryngeal cancer patients. Annual Meeting & OTO EXPO, American Academy of Otolaryngology - Head & Neck Surgery Foundation (the AAO-HNSF), San Diego, USA, 2008.

Johansson M, Rydén A, Finizia C. Communication problems and health-related quality of life (HRQL) in patients with laryngeal cancer: A prospective longitudinal study. Annual meeting of the Swedish Medical Association, Göteborg, 2008.

Johansson M, Rydén A, Finizia C. Self Evaluation of Communication Experiences after Laryngeal Cancer. A longitudinal questionnaire study. Annual Meeting & OTO EXPO, American Academy of Otolaryngology - Head & Neck Surgery Foundation (the AAO-HNSF) Chicago IL, USA, 2008.

Wahlquist P, Medin J, Rydén A. Responsiveness to change and clinically relevant improvements of the SF-36 questionnaire in Swedish patients with gastroesophageal reflux disease. ISPOR, 2009 (Value in Health 2009;12(3):A60).

Andersson O, Möller R, Rydén A, Ruth M. Presentation of a Laryngopharyngeal Reflux Questionnaire. Annual Meeting & OTO EXPO, American Academy of Otolaryngology - Head & Neck Surgery Foundation (the AAO-HNSF) Boston MA, USA, 2010.

Risberg-Berlin B, Möller R, Rydén A. 3 year follow-up; NAIM rehab in laryngectomized patients. Annual Meeting & OTO EXPO, American Academy of Otolaryngology - Head & Neck Surgery Foundation (the AAO-HNSF) Boston MA, USA, 2010.

Rydén A, Simrén M, Ringström G. Linguistic validation of the Swedish translation of the ROME III questionnaire. Swedish Gastro Meeting, Umeå, 2011.

Vakil N, Niklasson A, Denison H, Rydén A. Partial responders to a proton pump inhibitor in Gastroesophageal reflux disease: Symptom profile and prevalence of irritable bowel syndrome, anxiety and depression. DDW, Chicago, 2011 (Gut 2011;60 (Suppl 3), A 266).

Vakil N, Björck K, Halling K, Paty J, Karlsson M, Denison H, Rydén A. Validation of a patient reported outcome instrument, the Reflux Symptom Questionnaire electronic Diary, in patients with a partial response to proton pump inhibitor therapy. DDW, Chicago, 2011 (Gut 2011;60 (Suppl 3), A 266).

Vakil N, Karlsson M, Denison H, Rydén A. A patient reported outcome instrument in partial responders to proton pump inhibitor therapy suggest new symptoms deserve consideration: Results of a validation study. DDW, Chicago, 2011 (Gut 2011;60 (Suppl3), A 266).

Vakil N, Niklasson A, Denison H, Rydén A. Symptom profile and prevalence of irritable bowel syndrome, anxiety and depression in partial responders to proton pump inhibitor therapy. DDW, San Diego, 2012 (Gastroenterology 2012;142:5 (Suppl 1), P S-589).

Vakil N, Karlsson M, Denison H, Rydén A. The development of a patient reported outcome instrument in partial responders to proton pump inhibitor therapy suggests new symptoms deserve consideration: results of a validation study. DDW, San Diego, 2012 (Gastroenterology 2012;142:5 (Suppl 1), P S-422).

Vakil N, Niklasson A, Denison H, Rydén A. Symptom pattern in gastroesophageal reflux disease: comparison with treatment-naïve patients suggests overlapping disease entities in partial responders to proton pump inhibitor therapy. DDW, San Diego, 2012 (Gastroenterology 2012;142:5 (Suppl 1), P S-589-S-590).

Vakil N, Niklasson A, Denison H, Rydén A. Partial responders to proton pump inhibitor therapy have higher symptom scores for reflux, abdominal pain and constipation than treatment-naïve patients. UEGW, Stockholm, 2012.

Vakil N, Niklasson A, Denison H, Rydén A. Irritable bowel syndrome, anxiety and depression are not more prevalent in partial responders to proton pump inhibitor than in the general population with gastroesophageal reflux disease. UEGW, Stockholm, 2012.

Grandy S, Rydén A, Sugg J, Rohwedder K. Weight-related quality of life and treatment satisfaction among type 2 diabetes mellitus patients treated with dapagliflozin in triple-therapy regimen. ADA, San Fransisco, 2014.

Martin M, Wolfe M, Rydén A. What treatment benefits are important to patients with ESRD on hemodialysis? ASN Kidney Week Annual Meeting, Philadelphia, 2014.

Wysham C, Vieke D, Vetter M, Yaohua H, Nayyar I, Hardy E, Rydén A, Rosenstock J. Patient-Reported Treatment Satisfaction with Exenatide Once Weekly Suspension for Autoinjection (EQW-SAI) vs Exenatide Twice Daily (EBID) in Patients with Inadequately Controlled Type 2 Diabetes Mellitus (T2DM). ENDO, San Diego, 2015.

Grandy S, Chen S, Flood E, Romero B, Bergenheim K, Rydén A. GLP-1 device- and regimen-related treatment features important to injection- experienced and injection-naïve patients with type 2 diabetes mellitus: A multinational interview study. EASD, Stockholm, 2015.

Rydén A, Sörstadius E, Bergenheim K, Romanovschi A, Thorén F, Witt EA, Sternhufvud C. The humanistic and economic burden of Type 1 diabetes in Europe. EASD, Stockholm, 2015.

Sternhufvud C, Sörstadius E, Bergenheim K, Romanovschi A, Thorén F, Witt EA, Rydén A. Humanistic and economic outcomes of people with Type 1 diabetes in Europe with various degrees of complication. EASD, Stockholm, 2015.

Rydén A, Lawrance R, Papadakis K, Ghiorghiu S, Walding A. Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer. ECC, Vienna, 2015.

Rydén A, Braam L, Martin M, Walding A. Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: a qualitative interview substudy. ECC, Vienna, 2015.

Rudell K, Degboe A, Cimms T, Eek D, Ryden A, Halling K. Comparing the oncology PRO label claims for EU and US – What is the evidence? ISPOR, Washington, 2016.

Rudell K, Papadakis K, Bodnar C, Hoyle C, Ghiorghiu S, Rydén A. The impact of osimertinib on function and health status for patients with EGFR mutation-positive advanced non-small cell lung cancer. ASCO, Chicago, 2016.

Edvardsson N, Coyne K, Rydén A. Development and validation of the AFImpact: an atrial fibrillation-specific measure of patient-reported health-related quality of life. Heart Rhythm, Chicago, 2017.

Sebastian M, Rydén A, Walding A, Ghiorghiu S, Rudell K, Papadimitrakoulou V. Adverse events self-reported by patients with advanced non-small-cell lung cancer treated with osimertinib or chemotherapy. ELCC, Geneva, 2017.

Karlson BW, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Li J, Shen Z, Ryden A, Ahlqvist M, Sunden M, Du X, Ma C. Rationale, design, and baseline characteristics of a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China (eHelp China). EAS, Prague, 2017.

Du X, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Li J, Shen Z, Rydén A, Ahlqvist M, Sundén M, Karlson BW, Ma C. eHelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China. ESC, Barcelona, 2017.

Du X, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Li J, Shen Z, Ryden A, Ahlqvist M, Sundén M, Karlson BW, Ma C. eHelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China. Great Wall International Congress of Cardiology, Beijing, 2017.

Rydén A, Ollis S, Love E, Shields A, Jiang H, Dennis P. Understanding the patient perspective of small cell lung cancer (SCLC). ELCC, Geneva, 2018.

Leighl N, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Rydén A, Novello S. Patient-reported outcomes from FLAURA: osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFRmutated advanced non-small cell lung cancer (NSCLC). ELCC, Geneva, 2018.

Du X, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Li J, Shen Z, Ryden A, Ahlqvist M, Sundén M, Karlson BW, Ma C. eHelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China. EAS Congress, Lisbon, Portugal, 2018.

Gray JE, Karaseva N, Nakagawa K, Cho BC, Leighl N, Hovey T, Walding A, Rydén A, Novello S. Patient-reported outcomes from FLAURA: osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). AMPC, Boston, 2018.

Garon E, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, le Moulec S, Natale R, Schneider J, Shepherd F, Garassino MC, Geater SL, Szekely ZP, Tran N, Liu F, Scheuring U, Rydén A, Peters S, Rizvi N. Patient-reported outcomes with first-line durvalumab ± tremelimumab vs chemotherapy in metastatic NSCLC: results from MYSTIC. ASCO, Chicago, 2019.

Elkins I, Bordoni R, Shenolikar R, Rydén A, Martin ML, Bakker NA, Chung H, Feldman J. Experiences of patients on 1st line care (EP1C): symptoms and impacts of EGFR-TKI therapy on real-world daily lives of NSCLC patients. WCLC, Barcelona, 2019.

Casamayor M, Niklasson A, Reany M, Ivanescu C, Gwaltney C, Rydén A. Is there a need for a consensus on how to synthesize a single meaningful within-patient change threshold from different sources? ISPOR Eur 2020.

Zettl H, Rydén A, Racine C, van den Bos M, Fragoso R, Rohrbacher M, Ingelgård A. Capturing patients’ overall experience of HER2-mutation-positive non-small-cell lung cancer in a clinical trial: a qualitative interview substudy. ISOQOL, Cologne, 2024.

Sullivan M, Karlsson J, Rydén A. Measuring quality of life in overweight and obese. Rössner S, Lindroos A-K (eds) Obesity. From gene to societal influence. Lund: Studentlitteratur; 2007.

Elfström, M, Rydén A, Kreuter, M. Coping strategies: New specific questionnaires for measuring mastery and mental well being in the spinal cord lesioned. Swedish Rehabilitation, 2002, 1:9-11.

Jönsson N, Bootman JL, Eichler H-G, Moerman D, Moerman D, Rydén A. Patient experiences and the values of medicines, Internation Forum on Medicines/FIP, Sep 2004 (http://212.204.211.251/projects/ifom/pdf/brochur4.pdf).

Jönsson B, Rydén A. Does the medicine help? Medikament, 2005, 1:58-62.

Interpreting health-related Quality of Life. 4th Annual Conference of the International Society for Quality of Life Research, Wien, 1997.

The challenges of response shift: Theoretical, methodological and applied perspectives. Karolinska Institutet, Stockholm, 1998.

Dynamic Adaptive Testing. 6th Annual Conference of the International Society for Quality of Life Research, Barcelona, 1999.

Anxiety and coping with stress and illness: Assessment and application. 27thInternationel Congress of Psychology, Stockholm, 2000.

Anxiety and coping with stress and illness: Assessment and application. 27thInternationel Congress of Psychology, Stockholm, 2000.

An introduction to Rasch analysis: Concepts and application. 7th Annual Conference of the International Society for Quality of Life Research, Vancouver, 2000.

Everything you wanted to know about modern psychometric methods but were too afraid to ask. ISOQOL, London, 2010.

Principles of Patient Adherence & Support Solutions. Centre for Executive Leadership (C.E.L.forpharma) (http://www.celforpharma.com/course/principles-patient-adherence-support-solutions), 2016.